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Specific inhibition of 
acetylcholinesterase as an 
approach to decrease muscarinic 
side effects during myasthenia 
gravis treatment
Konstantin A. Petrov1,2, Alexandra D. Kharlamova1, Oksana A. Lenina1, Ayrat R. Nurtdinov3, 
Marina E. Sitdykova3, Victor I. Ilyin  2, Irina V. Zueva1 & Evgeny E. Nikolsky1,3,4
Non-selective inhibitors of cholinesterases (ChEs) are clinically used for treatment of myasthenia 
gravis (MG). While being generally safe, they cause numerous adverse effects including induction of 
hyperactivity of urinary bladder and intestines affecting quality of patients life. In this study we have 
compared two ChEs inhibitors, a newly synthesized compound C547 and clinically used pyridostigmine 
bromide, by their efficiency to reduce muscle weakness symptoms and ability to activate contractions 
of urinary bladder in a rat model of autoimmune MG. We found that at dose effectively reducing 
MG symptoms, C547 did not affect activity of rat urinary bladder. In contrast, at equipotent dose, 
pyridostigmine caused a significant increase in tonus and force of spontaneous contractions of 
bladder wall. We also found that this profile of ChEs inhibitors translates into the preparation of 
human urinary bladder. The difference in action observed for C547 and pyridostigmine we attribute to 
a high level of pharmacological selectivity of C547 in inhibiting acetylcholinesterase as compared to 
butyrylcholinesterase. These results raise reasonable hope that selective acetylcholinesterase inhibitors 
should show efficacy in treating MG in human patients with a significant reduction in adverse effects 
related to hyperactivation of smooth muscles.
Synaptic transmission at the skeletal neuromuscular junction (NMJ) is indispensable for survival of living organ-
isms by transducing complexity of cerebral commands to muscular twitches. In the vertebrate NMJ presynaptic 
electrical signal is transmitted by acetylcholine (ACh) which is released from motor nerve ending, and then 
diffuses through synaptic cleft to activate postsynaptic nicotinic acetylcholine receptors (nAChRs) of muscle 
type ((α1)2β1δε)1. This, in turn, leads to membrane depolarization (postsynaptic excitatory potential), triggering 
action potential (AP) and muscle twitch. Impairment of neuromuscular synaptic transmission results in muscle 
weakness and even death if synapses of respiratory muscles are affected.
The most common form of pathological muscle weakness is myasthenia gravis (MG). This chronic autoim-
mune neuromuscular disorder is characterized by fluctuating weakness of voluntary muscle groups. Weakness 
in MG is caused by autoantibodies directed specifically and primarily towards muscle type nAChRs. Antibodies 
reduce the number of functional nAChRs in the NMJs by a combination of complement-mediated membrane 
lysis and acceleration of receptor catabolism2,3. The cause of autoimmune response is unknown and only sympto-
matic therapies for MG are currently available. Clinically relevant treatments of MG include immunosuppressive 
drugs, plasmapheresis, thymectomy and inhibitors of cholinesterases (ChEs)4. All treatments suffer from a variety 
of side effects. For daily pharmacological correction of muscle weakness, the most frequently used drugs cause 
partial inhibition of AChE and butyrylcholinesterase (BChE). These enzymes catalyze hydrolysis of ACh, thus 
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